NICE announces more people eligible for nusinersen following review of Managed Access Agreement

NICE has today (4 May 2021) announced that more people with the rare genetic disorder spinal muscular atrophy (SMA) are to benefit from nusinersen (also called Spinraza and made by Biogen) following a review of data collected as part of the Managed Access Agreement (MAA).

Read news story

  1. NICE signs up to join the GetReal Institute

    NICE’s ambition complements the GetReal Institute’s core mission to facilitate the adoption and implementation of real-world evidence in health care decision-making.


NICE Talks podcasts

NICE Talks brings you the real life experiences of people working within the NHS, public health and social care.

You will hear the stories behind our work to improve care across the country through evidence-based guidance.

Press and media

Contact the press office: 07973 970 534 |